Psilocybin molecule:

Image from PubChem

Psilocybin Clinical Trials

Phase I Study of the Safety and Adjunctive Effects of Psilocybin in Adults With Opioid Use Disorder Maintained on Buprenorphine/Naloxone

To see complete record on, please visit this link

Id: NCT04161066

Organisation Name: University of Wisconsin, Madison

Overal Status: Active, not recruiting

Start Date: January 13, 2021

Last Update: August 22, 2022

Lead Sponsor: University of Wisconsin, Madison

Brief Summary: Primary Aim: In participants with OUD in early or sustained full recovery on buprenorphine/naloxone therapy, to characterize adverse events associated with adding two psilocybin doses to a stable buprenorphine/naloxone regimen.

Secondary Aim: To evaluate the effect of psilocybin treatment on the effectiveness of buprenorphine/naloxone maintenance therapy.

Secondary Aim: To evaluate the effect of concurrent buprenorphine/naloxone use on the effects of psilocybin therapy.

Descriptive Aim: To describe any changes in self-efficacy, quality of life, pain.

  • Opioid Use Disorder

Total execution time in seconds: 0.49130415916443